HER2靶向ADC药物致眼表微结构与神经损伤的前瞻性纵向研究
该前瞻性纵向研究纳入21例接受HER2靶向抗体药物偶联物(ADC)治疗的HER2阳性乳腺癌患者,评估眼表毒性。结果显示85.7%(18/21)患者出现眼表毒性,平均发病时间28.0±8.4天,表现为涡状角膜病变、角膜神经纤维断裂丢失及敏感度下降,损伤呈剂量和时间依赖性且部分可逆。
要点
- HER2-ADC治疗患者眼表毒性发生率达85.7%(18/21),平均28.0±8.4天出现。
- 涡状角膜病变从下方上皮下微囊肿进展为线状沉积和涡状图案。
- IVCM显示上皮下神经纤维严重断裂丢失,TEM示线粒体损伤和核改变。
核心结论
- HER2-ADC诱导的眼表毒性表现为视力下降、干眼及角膜上皮(涡状角膜病变)和神经(神经纤维丢失、敏感度降低)的选择性损伤,呈剂量和时间依赖性且部分可逆。
研究设计与样本
- 前瞻性纵向研究纳入21例接受HER2-ADC治疗的HER2阳性乳腺癌患者,基线至随访比较各参数。
- 评估包括最佳矫正视力、眼表疾病指数、结膜丽丝胺绿染色、泪膜破裂时间、泪河高度、睑板腺评分、SMTube试纸、角膜敏感度、前节OCT和活体共聚焦显微镜(IVCM)。
- 部分病例行透射电子显微镜(TEM)检查。
主要发现
- 眼表毒性发生于85.7%(18/21)患者,平均发病时间28.0±8.4天。
- 涡状角膜病变从下方上皮下微囊肿进展为线状沉积和涡状图案。
- IVCM显示上皮下神经纤维严重断裂和丢失。
- TEM显示上皮细胞外基质纤维化、线粒体损伤(肿胀、嵴紊乱、空泡化)、核改变(染色质分散、电子致密沉积)和疑似内吞囊泡。
- 病变呈剂量和时间依赖性,12周期后角膜结构和透明度呈恢复趋势。
临床怎么用
- 接受HER2-ADC治疗的乳腺癌患者应监测眼表毒性,包括角膜敏感度和IVCM评估。
- 涡状角膜病变和神经纤维丢失为特征性表现,损伤部分可逆,支持早期识别和干预。
局限性
- 样本量较小(21例),TEM仅用于部分病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To characterise the clinical and morphological features of ocular surface toxicity induced by human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in patients with HER2-positive breast cancer, guiding clinical intervention. METHODS: 21 HER2-positive breast cancer patients receiving HER2-ADC therapy were enrolled. Assessments included best corrected visual acuity, the Ocular Surface Disease Index, conjunctival lissamine green staining, tear break-up time, tear meniscus height, Meibomian Gland Score, Strip Meniscometry Tube (SMTube strips), corneal sensitivity (Cochet-Bonnet esthesiometry), anterior segment optical coherence tomography and in vivo confocal microscopy (IVCM) to evaluate morphology, corneal nerve fibre density and length, and endothelial cell density. Transmission electron microscopy (TEM) was performed in selected cases. All parameters were compared from baseline to follow-up. RESULTS: Ocular surface toxicity occurred in 85.7% (18/21) of patients after HER2-ADC therapy, with a mean onset at 28.0±8.4 days. Vortex-like keratopathy progressed from inferior subepithelial microcysts to linear deposits and a vortex pattern. IVCM revealed severe subepithelial nerve fibre fragmentation and loss. TEM revealed epithelial extracellular matrix fibrosis, mitochondrial damage (swelling, disordered cristae, vacuolisation), nuclear alterations (chromatin dispersion, electron-dense deposits) and suspected endocytic vesicles. Lesions appeared dose- and time-dependent and showed partial reversibility. After 12 cycles, corneal structure and transparency showed restoration trends. CONCLUSION: HER2-ADC-induced ocular surface toxicity presents as vision loss, dry eye and selective damage to corneal epithelium (vortex-like keratopathy) and nerves (nerve fibre loss and reduced sensitivity), which is dose- and time-dependent and partially reversible.
引用
- Yang L, Cui M, Huang S, et al. Microstructural and neural impairment of the ocular surface induced by HER2-targeted ADCs: a prospective longitudinal study with ultrastructural insights. Br J Ophthalmol. 2026. PMID: 42331364. doi:10.1136/bjo-2026-329526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。